Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BIOYF BIOSYENT INC
5.290
+0.020+0.38%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
1.50% 6.79M -8.98% 6.63M -5.15% 7.04M 28.15% 28.62M
Operating revenue
1.50% 6.79M -8.98% 6.63M -5.15% 7.04M 28.15% 28.62M
Cost of revenue
-17.56% 1.18M -26.19% 1.17M -7.50% 1.45M 21.84% 5.98M
Gross profit
6.70% 5.61M -4.19% 5.46M -4.53% 5.59M 29.92% 22.64M
Operating expense
19.92% 3.8M -8.49% 3.91M -2.78% 3.44M 17.01% 14.39M
Selling and administrative expenses
23.61% 3.66M -8.85% 3.76M -1.66% 3.3M 18.55% 13.66M
-Selling and marketing expense
-19.15% 1.56M -32.07% 1.3M 2.19% 1.41M 22.27% 9.08M
-General and administrative expense
103.48% 2.1M 11.19% 2.46M -4.35% 1.89M 11.82% 4.58M
Research and development costs
-61.88% 38.11K 106.94% 51.8K -37.68% 36.82K 14.48% 276.54K
Depreciation amortization depletion
-6.50% 97.52K -19.93% 98.22K -16.92% 99.89K -8.59% 457.11K
-Depreciation and amortization
-6.50% 97.52K -19.93% 98.22K -16.92% 99.89K -8.59% 457.11K
Provision for doubtful accounts
-- -- -- -- -- -- -- 0
Operating profit
-13.36% 1.81M 8.67% 1.55M -7.20% 2.15M 60.91% 8.25M
Net non-operating interest income expense
1,154.63% 127.8K 521.00% 58.77K 52.71% 22.7K -69.56% 51.8K
Non-operating interest income
367.62% 146.99K 152.75% 78.27K 16.05% 42.49K -47.92% 137.05K
Non-operating interest expense
-9.66% 19.2K -9.31% 19.5K -9.00% 19.79K -8.28% 85.25K
Other net income (expense)
-58.41% 41.99K 164.59% 38.22K 69.31% -24.63K 234.27% 78.99K
Gain on sale of security
-58.41% 41.99K 164.59% 38.22K 69.31% -24.63K 21.79% -46.01K
Other non- operating income (expenses)
-- -- -- -- -- -- -- 125K
Income before tax
-10.02% 1.98M 19.63% 1.65M -4.59% 2.15M 59.99% 8.38M
Income tax
10.03% 526.25K 19.63% 431.25K -4.59% 562.27K 45.45% 2.1M
Net income
-15.59% 1.45M 19.63% 1.22M -4.59% 1.59M 65.51% 6.28M
Net income continuous Operations
-15.59% 1.45M 19.63% 1.22M -4.59% 1.59M 65.51% 6.28M
Minority interest income
Net income attributable to the parent company
-15.59% 1.45M 19.63% 1.22M -4.59% 1.59M 65.51% 6.28M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-15.59% 1.45M 19.63% 1.22M -4.59% 1.59M 65.51% 6.28M
Basic earnings per share
-12.50% 0.119 22.50% 0.098 -2.31% 0.127 70.69% 0.495
Diluted earnings per share
-13.43% 0.116 21.52% 0.096 -3.85% 0.125 68.28% 0.488
Dividend per share
Currency Unit
CADCADCADCAD
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System, Tibella, Combogesic, and Cysview. The company was founded on April 28, 1947 and is headquartered in Mississauga, Canada.
CEO: Mr. Rene C. Goehrum
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist